Yet again, a new acquisition in this beginning of 2015. Enzymatics, the Boston-area based Biotech company and leading provider of enzymes for Next-gen sequencing, has been acquired by Qiagen for a non-disclosed amount. The amount must be pretty high since Enzymatics’ enzymes are used in 80% of all NGS reactions and the company counts over 150 employees.

Enzymatic is the 3rd Boston-based company, featured in LaBiotech Tour Boston, and just brought major news on the table this week (after Moderna and Foundation Medicine). I visited the company, which is based in Beverly 30-minutes north of Boston by train. I discovered a great company, co-founded by the genetics rock-star George Church (also in the documentary here) who also contributed massively to the price decrease in NGS. I let Ian Ratcliffe, former CEO and Board Chairman present you the company:

The addition of this Enzymatics franchise adds a deep portfolio of capabilities to QIAGEN‘s strategy to offer a complete NGS workflow from biological samples to valuable molecular insights as well as to strengthen its broad and rapidly growing portfolio of “universal” NGS products compatible with any sequencer. The Enzymatics portfolio that has just been acquired will be commercialized globally through QIAGEN’s direct, indirect and OEM channels.

“Enzymatics has distinguished itself as a premier enabler of the emergence of affordable, widely usable NGS sequencing“, said Peer M. Schatz, CEO of QIAGEN. “These solutions are a perfect fit with our leading offering of universal NGS products as well as with our strategy to develop integrated workflows that will help to drive the adoption of NGS in clinical healthcare. We are committed to supporting the global sequencing community through continued access to the solutions and products from Enzymatics’ world-class capabilities.”

Qiagen will benefit from Enzymatics’ extensive experience in the Next-gen sequencing field and control an additional part of its value chain. A new giant in the field of Next-gen sequencing tools is born.

Previous post

Everyone here at LaBiotech.eu want to say thank you for following us!

Next post

LaBiotech.eu's most-read articles since our start!